Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention.

Kogan M, Rappaport J.

Retrovirology. 2011 Apr 13;8:25. doi: 10.1186/1742-4690-8-25. Review.

2.

HIV-1 accessory proteins: VpR.

Zhao RY, Bukrinsky MI.

Methods Mol Biol. 2014;1087:125-34. doi: 10.1007/978-1-62703-670-2_11.

3.

Quantitative Temporal Viromics of an Inducible HIV-1 Model Yields Insight to Global Host Targets and Phospho-Dynamics Associated with Protein Vpr.

Lapek JD Jr, Lewinski MK, Wozniak JM, Guatelli J, Gonzalez DJ.

Mol Cell Proteomics. 2017 Aug;16(8):1447-1461. doi: 10.1074/mcp.M116.066019. Epub 2017 Jun 12.

4.

Differential effects of Vpr on single-cycle and spreading HIV-1 infections in CD4+ T-cells and dendritic cells.

de Silva S, Planelles V, Wu L.

PLoS One. 2012;7(5):e35385. doi: 10.1371/journal.pone.0035385. Epub 2012 May 3.

5.

HIV1-viral protein R (Vpr) mutations: associated phenotypes and relevance for clinical pathologies.

Soares R, Rocha G, Meliço-Silvestre A, Gonçalves T.

Rev Med Virol. 2016 Sep;26(5):314-29. doi: 10.1002/rmv.1889. Epub 2016 Jun 6. Review.

PMID:
27264019
6.

Vpr-host interactions during HIV-1 viral life cycle.

Zhao RY, Li G, Bukrinsky MI.

J Neuroimmune Pharmacol. 2011 Jun;6(2):216-29. doi: 10.1007/s11481-011-9261-z. Epub 2011 Feb 12. Review.

7.

Modulation of NKG2D-mediated cytotoxic functions of natural killer cells by viral protein R from HIV-1 primary isolates.

Pham TN, Richard J, Gerard FC, Power C, Cohen ÉA.

J Virol. 2011 Dec;85(23):12254-61. doi: 10.1128/JVI.05835-11. Epub 2011 Sep 28. Erratum in: J Virol. 2012 Feb;86(3):1902.

8.

Evidence for Vpr-dependent HIV-1 replication in human CD4+ CEM.NKR T-cells.

Zhou T, Dang Y, Baker JJ, Zhou J, Zheng YH.

Retrovirology. 2012 Nov 7;9:93. doi: 10.1186/1742-4690-9-93.

9.

Cullin4A and cullin4B are interchangeable for HIV Vpr and Vpx action through the CRL4 ubiquitin ligase complex.

Sharifi HJ, Furuya AK, Jellinger RM, Nekorchuk MD, de Noronha CM.

J Virol. 2014 Jun;88(12):6944-58. doi: 10.1128/JVI.00241-14. Epub 2014 Apr 9.

10.

Insights into the biology of HIV-1 viral protein R.

Sherman MP, De Noronha CM, Williams SA, Greene WC.

DNA Cell Biol. 2002 Sep;21(9):679-88. Review.

PMID:
12396611
11.

HIV-1 Vpr accelerates viral replication during acute infection by exploitation of proliferating CD4+ T cells in vivo.

Sato K, Misawa N, Iwami S, Satou Y, Matsuoka M, Ishizaka Y, Ito M, Aihara K, An DS, Koyanagi Y.

PLoS Pathog. 2013;9(12):e1003812. doi: 10.1371/journal.ppat.1003812. Epub 2013 Dec 5.

12.

Virion encapsidated HIV-1 Vpr induces NFAT to prime non-activated T cells for productive infection.

Höhne K, Businger R, van Nuffel A, Bolduan S, Koppensteiner H, Baeyens A, Vermeire J, Malatinkova E, Verhasselt B, Schindler M.

Open Biol. 2016 Jul;6(7). pii: 160046. doi: 10.1098/rsob.160046.

13.

The HIV-1 Vif protein mediates degradation of Vpr and reduces Vpr-induced cell cycle arrest.

Wang J, Shackelford JM, Selliah N, Shivers DK, O'Neill E, Garcia JV, Muthumani K, Weiner D, Yu XF, Gabuzda D, Finkel TH.

DNA Cell Biol. 2008 May;27(5):267-77. doi: 10.1089/dna.2007.0707.

PMID:
18462066
14.

Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection.

Hrimech M, Yao XJ, Bachand F, Rougeau N, Cohen EA.

J Virol. 1999 May;73(5):4101-9.

15.

Defining the roles for Vpr in HIV-1-associated neuropathogenesis.

James T, Nonnemacher MR, Wigdahl B, Krebs FC.

J Neurovirol. 2016 Aug;22(4):403-15. doi: 10.1007/s13365-016-0436-5. Epub 2016 Apr 7. Review.

16.

HIV-1 Vpr redirects host ubiquitination pathway.

Arora S, Verma S, Banerjea AC.

J Virol. 2014 Aug;88(16):9141-52. doi: 10.1128/JVI.00619-14. Epub 2014 Jun 4.

17.

HIV-1 Vpr: a closer look at the multifunctional protein from the structural perspective.

Pandey RC, Datta D, Mukerjee R, Srinivasan A, Mahalingam S, Sawaya BE.

Curr HIV Res. 2009 Mar;7(2):114-28. Review.

PMID:
19275580
18.

Inhibition of human immunodeficiency virus type 1 (HIV-1) nuclear import via Vpr-Importin alpha interactions as a novel HIV-1 therapy.

Suzuki T, Yamamoto N, Nonaka M, Hashimoto Y, Matsuda G, Takeshima SN, Matsuyama M, Igarashi T, Miura T, Tanaka R, Kato S, Aida Y.

Biochem Biophys Res Commun. 2009 Mar 20;380(4):838-43. doi: 10.1016/j.bbrc.2009.01.180. Epub 2009 Feb 4.

PMID:
19338763
19.

Exposed hydrophobic residues in human immunodeficiency virus type 1 Vpr helix-1 are important for cell cycle arrest and cell death.

Barnitz RA, Chaigne-Delalande B, Bolton DL, Lenardo MJ.

PLoS One. 2011;6(9):e24924. doi: 10.1371/journal.pone.0024924. Epub 2011 Sep 16.

20.

Human immunodeficiency virus type 1 Vpr polymorphisms associated with progressor and nonprogressor individuals alter Vpr-associated functions.

Hadi K, Walker LA, Guha D, Murali R, Watkins SC, Tarwater P, Srinivasan A, Ayyavoo V.

J Gen Virol. 2014 Mar;95(Pt 3):700-11. doi: 10.1099/vir.0.059576-0. Epub 2013 Dec 3.

Supplemental Content

Support Center